SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 3.27%29.0714.1%$171.05m
ICLRICON plc 0.93%229.204.2%$156.70m
JAZZJazz Pharmaceuticals Plc 0.57%179.172.2%$142.15m
HZNPHorizon Therapeutics Plc 5.02%92.145.5%$124.53m
CTLTCatalent, Inc. 2.18%102.672.1%$105.63m
BHCBausch Health Cos., Inc. 3.27%29.070.0%$91.68m
SAVACassava Sciences, Inc. 8.31%40.920.0%$55.78m
UTHRUnited Therapeutics Corp. 2.12%197.8714.0%$55.65m
PRGOPerrigo Co. Plc 1.80%45.826.9%$49.71m
BLRXBioLineRx Ltd. 0.00%2.850.8%$38.97m
ARGXargenx SE 4.22%272.300.0%$38.23m
SAGESAGE Therapeutics, Inc. 2.03%70.867.6%$33.60m
PCRXPacira Biosciences, Inc. 1.22%62.219.9%$30.64m
AXSMAxsome Therapeutics, Inc. -2.68%58.421.9%$26.79m
RVMDRevolution Medicines, Inc. 4.07%31.990.0%$23.38m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.